Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Research Article

Rheumatologic Manifestations of Post SARS-CoV-2 Infection: A Case Series

Author(s): Samy Metyas*, Christina Chen, Tun Aung, Andrew Ballester and Sovanndy Cheav

Volume 18, Issue 4, 2022

Published on: 18 April, 2022

Page: [346 - 351] Pages: 6

DOI: 10.2174/1573397118666220211155716

Price: $65

Abstract

Background: It has been over a year since the first documented case of the COVID-19 virus was recorded. Since then, our understanding of this virus has continually evolved, however, its wide-ranging effects are still unfolding. Similar to previously studied viral infections, severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2) has been shown to lead to a degree of autoimmunity in patients who are recovering from its effects. Due to its effects on the innate immune system, such as the toll-like receptors and complement system, a varying degree of proinflammatory markers can become widespread in those who continue to recover from the virus. This case series offers a unique perspective on how COVID-19 has had dramatic effects on those already suffering from inflammatory rheumatic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, or fibromyalgia. As the ever-lasting effects of COVID-19 are still unfolding, this case series is one of few to discuss the development and changes of patients with rheumatic conditions. This study hopes to encourage larger studies to be conducted on the effects of COVID- 19 on autoimmune conditions.

Case Presentation: Seven patients were identified with new manifestations of rheumatic conditions, which included 3 cases of rheumatoid arthritis, 2 cases of polymyalgia rheumatica, 1 case of reactive arthritis, and 1 case of cutaneous lupus. Post-COVID syndrome was also diagnosed in 7 other patients.

Patients with rheumatoid arthritis presented with symptoms 4-5 weeks after being diagnosed with COVID-19. Symptoms of polyarticular joint pain, swelling, and morning stiffness were reported in this group. These patients were treated with disease-modifying anti-rheumatic drugs and experienced an improvement in symptoms on follow-up.

Two cases of polymyalgia rheumatica were identified in patients that were previously diagnosed with COVID-19 six weeks prior. One patient had no significant past medical history and the other patient had a history of rheumatoid arthritis, which was well controlled. These patients experienced weakness and tenderness in the proximal joints with elevated levels of ESR and CRP. They were treated with prednisone and showed improvement.

Reactive arthritis was diagnosed in 1 patient who presented with swelling in both hands and wrists 2 days after being diagnosed with COVID-19. This patient began to experience symptoms of reactive arthritis 2 days after resolution of initial COVID-19 symptoms and this persisted for 3 months. The patient was managed with methylprednisolone injections and NSAIDs, which improved her symptoms.

Post-COVID syndrome was identified in 7 patients. All patients were female and had a history of well-controlled fibromyalgia. Patients generally experienced fatigue, headaches, and memory fog, which had variable onset from a few days and up to 4 weeks after being diagnosed with COVID-19. One patient had a complete recovery of her symptoms at follow-up 3 months after the initial presentation. The other 6 patients continued to report symptoms of post-COVID syndrome at follow-up. Patients were managed with lifestyle modifications and their previous fibromyalgia treatment.

Conclusion: While cases of COVID-19 continue to rise, complications of this disease are still being discovered. Those who initially recover from COVID-19 may experience new-onset rheumatic conditions, worsening of previously diagnosed rheumatic conditions, or post-COVID syndrome. As we continue to learn more about the effects of COVID-19, the awareness of these manifestations will play a key role in the appropriate management of these patients.

Keywords: Post-COVID, rheumatological manifestation, disease flare, post-Covid syndrome, rheumatoid arthritis, COVID 19, reactive arthritis.

[1]
Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy 2020; 75(7): 1564-81.
[2]
Vellas C, Delobel P, de Souto Barreto P, Izopet J. COVID-19, virology and geroscience: A perspective. J Nutr Health Aging 2020; 24(7): 685-91.
[http://dx.doi.org/10.1007/s12603-020-1416-2] [PMID: 32744561]
[3]
Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 infections, symptomatic infections, hospitalizations, and deaths using seroprevalence surveys. JAMA Network Open 2021; 4(1): e2033706.
[4]
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 324(8): 782-93.
[http://dx.doi.org/10.1001/jama.2020.12839] [PMID: 32648899]
[5]
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021; 20(4): 102792.
[http://dx.doi.org/10.1016/j.autrev.2021.102792] [PMID: 33610751]
[6]
Peral-Garrido ML, Calabuig I, Tovar-Sugrañes E, et al. Case series of acute arthritis during COVID-19 admission. Ann Rheum Dis 2021; 80(4): e58-.
[7]
Raghavan S, Gonakoti S, Asemota IR, Mba B. A case of systemic lupus erythematosus flare triggered by severe coronavirus disease 2019. J Clin Rheumatol 2020; 26(6): 234-5.
[http://dx.doi.org/10.1097/RHU.0000000000001531] [PMID: 32826658]
[8]
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27(4): 601-15.
[http://dx.doi.org/10.1038/s41591-021-01283-z] [PMID: 33753937]
[9]
Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 2021; 40(7): 2611-9.
[http://dx.doi.org/10.1007/s10067-021-05691-x] [PMID: 33733315]
[10]
Sawadogo SA, Dighero-Kemp B, Ouédraogo DD, Hensley L, Sakandé J. How NETosis could drive “Post-COVID-19 syndrome” among survivors. Immunol Lett 2020; 228: 35-7.
[http://dx.doi.org/10.1016/j.imlet.2020.09.005] [PMID: 33007368]
[11]
Chauhan K, Jandu JS, Goyal A, Bansal P, Al-Dhahir MA. Rheumatoid Arthritis.StatPearls. Treasure Island, FL: StatPearls Publishing 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK/441999/
[12]
Cheeti A, Chakraborty RK, Ramphul K. Reactive Arthritis.StatPearls. Treasure Island, FL: StatPearls Publishing 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499831/
[13]
Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open 2020; 6(2): e001350.
[http://dx.doi.org/10.1136/rmdopen-2020-001350] [PMID: 32763956]
[14]
Liew IY, Mak TM, Cui L, Vasoo S, Lim XR. A case of reactive arthritis secondary to Coronavirus Disease 2019 infection. J Clin Rheumatol 2020; 26(6): 233.
[http://dx.doi.org/10.1097/RHU.0000000000001560] [PMID: 32694352]
[15]
Acharya S, Musa R. Polymyalgia Rheumatica.StatPearls. Treasure Island, FL: StatPearls Publishing 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537274/
[16]
Hemauer A, Modrow S, Georgi J, et al. There is no association between polymyalgia rheumatica and acute parvovirus B19 infection. Ann Rheum Dis 1999; 58(10): 657-8.
[http://dx.doi.org/10.1136/ard.58.10.657] [PMID: 10577374]
[17]
Narváez J, Clavaguera MT, Nolla-Solé JM, Valverde-Garcia J, Roig-Escofet D. Lack of association between infection and onset of polymyalgia rheumatica. J Rheumatol 2000; 27(4): 953-7.
[PMID: 10782822]
[18]
Bingham CO III, Pohl C, Woodworth TG, et al. Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009; 36(10): 2335-41.
[http://dx.doi.org/10.3899/jrheum.090369] [PMID: 19684147]
[19]
Yılmaz V, Umay E, Gündoğdu İ, Karaahmet ZÖ, Öztürk AE. Rheumatoid arthritis: Are psychological factors effective in disease flare? Eur J Rheumatol 2017; 4(2): 127-32.
[http://dx.doi.org/10.5152/eurjrheum.2017.16100] [PMID: 28638686]
[20]
Davido B, Seang S, Tubiana R, de Truchis P. Post-COVID-19 chronic symptoms: a postinfectious entity? Clin Microbiol Infect 2020; 26(11): 1448-9.
[http://dx.doi.org/10.1016/j.cmi.2020.07.028] [PMID: 32712242]
[21]
Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: Post-viral syndrome post COVID-19. Med Hypotheses 2020; 144: 110055.
[http://dx.doi.org/10.1016/j.mehy.2020.110055] [PMID: 32758891]
[22]
Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syn-drome; a case-controlled study. BMC Neurol 2011; 11(1): 37.
[http://dx.doi.org/10.1186/1471-2377-11-37] [PMID: 21435231]
[23]
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology 2020; 95(8): e1060-70.
[http://dx.doi.org/10.1212/WNL.0000000000009937] [PMID: 32482845]
[24]
Novelli L, Motta F, Ceribelli A, et al. A case of psoriatic arthritis triggered by SARS-CoV-2 infection. Rheumatology 2020; 60(1): e21-3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717387/

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy